Treatment-refractory Metastatic Breast Cancer: New Options & Emerging Strategies ArcMesa Educators
ArcMesa Educators Home
podcast Home Faculty Accreditation Program Posttest Contact

Release Date: December 11, 2008
Expiration Date: December 31, 2009

Program Description

Join us as leading experts in the field of metastatic breast cancer discuss the challenges and therapeutic options for the management of treatment-refractory metastatic breast cancer. Dr Hudis begins with a review of evidence-based options for the management of HER 2+ breast cancer patients followed by Dr DeMichele who provides insight on standard chemotherapy options and future options for patients resistant to treatment. At the conclusion of the 1-hour webcast portion worth 1 CME credit, a lively interactive case based discussion is available that features Dr Toppmeyer and the faculty panel discussing their expert opinion on best practices for patients with advanced metastatic breast cancer.

Webcast Accreditation & Credit Designation

ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ArcMesa Educators designates this educational activity for a maximum of 1 AMA PRA Category 1 credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA category 1 credit™. Statement of credit will be available to print from your user history page.

Learning Objectives

Upon completion participants should be able to:

  1. Review the current clinical practice guidelines regarding the treatment of patients with treatment-refractory metastatic breast cancer
  2. Analyze the recent data regarding new and emerging treatment options for refractory patients
  3. Use effective strategies for managing patients with advanced and resistant breast cancer
  4. Discuss the evidence-based guidelines and available therapeutic options for HER2 positive breast cancer patients

Target Audience

This activity is intended for medical oncologists and practitioners who manage refractory breast cancer patients.

Faculty Disclosures

Deborah L. Toppmeyer, MD
This speaker has nothing to disclose.

Angela DeMichele, MD, MSCE
This speaker has nothing to disclose.

Clifford A. Hudis, MD
This speaker has disclosed the following:
Advisory board: Amgen, BMS, Genentech, GSK, Novartis, Pfizer, sanofi-aventis.
Grants/Research Support: AstraZeneca, BMS, Onyx Pharmaceutical.

Moderator

Deborah L. Toppmeyer, M.D.

Deborah L. Toppmeyer, MD
Associate Professor of Medicine
Robert Wood Johnson Medical School, UMDNJ
Director, NJ Comprehensive Breast Care Center
The Cancer Institute of New Jersey
New Brunswick, NJ

Faculty

Angela DeMichele, MD, MSCE

Angela DeMichele, MD, MSCE
Co-Director, Breast Program
Abramson Cancer Center of the University of Pennsylvania
Senior Scholar
Center for Clinical Epidemiology and Biostatistics
Philadelphia, PA

Clifford A. Hudis, MD

Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Staff Disclosure Declarations

The employees of ArcMesa Educators have no financial relationships to disclose.

Disclosure Policy

It is the policy of ArcMesa Educators that our staff and faculty disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentations. Individuals who refuse to disclose will be disqualified from all aspects of this CME activity. ArcMesa Educators has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

Acknowledgement of Sponsor

This activity is sponsored by ArcMesa Educators.

Acknowledgement of Commercial Support

This activity is multi-supported by an educational grant from Bristol-Myers Squibb and Eli Lilly and Company.
Bristol-Myers Squibb
Eli Lilly and Company

Disclaimer

©2008 ArcMesa Educators. All rights reserved. None of the contents may be reproduced in any form without prior written permission from ArcMesa Educators.

The views and opinions expressed in this activity are those of the faculty and do not in any way reflect those of ArcMesa Educators. They also do not represent the views of Bristol-Meyers Squibb, Eli Lilly and Company or any other manufacturer of pharmaceuticals.

The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating faculty. Any medications, diagnostic procedures or treatments discussed by the faculty should not be utilized without evaluation of their patient’s conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.

Hardware/Software Requirements

System Requirement: Windows 98, ME, 2000, XP, Vista; Mac OS X.
Windows: Intel Pentium II 450 mhz or faster processor (or equivalent), 128MB of RAM.
Mac: PowerPC G3 500mhz or faster processor, 128MB of RAM.
Internet/Network: Broadband connectivity.

ArcMesa Educators requires Microsoft Internet Explorer 5.5, Firefox 1.x, Netscape 7.x, Opera 7.11, Safari 1.x or later. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. That software may be: Adobe Flash Player 8, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

Technical Support & Customer Services

ArcMesa Educators, LLC
Address: 666 Plainsboro Rd, Suite 440, Plainsboro, NJ 08536
Phone: 609-630-6100 | Fax: 609-630-6110 | Email: customer_services@arcmesa.com


Copyright © 2009 ArcMesa Educators, LLC. All Rights Reserved. | Privacy Statement

All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.